WA
LRMR icon

WFG Advisors’s Larimar Therapeutics LRMR Stock Holding History

WFG Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-19
Closed -$7K – 1631
2015
Q3 		$7K Hold
19
– – ﹤0.01% 1184
2015
Q2 		$8K Hold
19
– – ﹤0.01% 1247
2015
Q1 		$9K Buy
+19
New +$9.02K ﹤0.01% 1237

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

WFG Advisors's LRMR Position: Q4 2015 in Review

WFG Advisors sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 19 shares — an estimated $7K sold.

WFG Advisors first reported a position in LRMR in Q1 2015 and held it in 3 quarters. The position peaked at $9K in Q1 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • WFG Advisors reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • WFG Advisors sold 19 Larimar Therapeutics shares in Q4 2015, an estimated $7K.
  • WFG Advisors first reported a position in Larimar Therapeutics in Q1 2015 and held it in 3 quarters.
  • WFG Advisors's Larimar Therapeutics position peaked at $9K in Q1 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on WFG Advisors's 13F filing for Q4 2015, filed 9 Feb 2016.